Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD3 | Q15059 | 7/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.44 |
| ▸ | PARP1 | P09874 | 2/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | CDC42 | P60953 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5456586 | 0.93 | BRD3 (0.45) | BRD3PARP1NAMPTCDC42GAA | |
| SCHEMBL5456602 | 0.93 | BRD3 (0.45) | BRD3ROCK2PARP1CDC42GAA | |
| SCHEMBL5461870 | 0.93 | ROCK2 (0.47) | BRD3ROCK2PARP1NAMPTCDK1 | |
| SCHEMBL5454096 | 0.91 | CDC42 (0.50) | ROCK2PARP1NAMPTCDC42GAA | |
| SCHEMBL5492905 | 0.91 | SMN1; SMN2 (0.48) | ROCK2PARP1CDC42GAACASP6 | |
| SCHEMBL5463485 | 0.89 | CDC42 (0.44) | BRD3ROCK2PARP1NAMPTCDC42 | |
| SCHEMBL5459002 | 0.89 | DHODH (0.47) | PARP1NAMPTCDC42GAACASP6 | |
| SCHEMBL5461879 | 0.89 | GAA (0.51) | PARP1CDC42GAACASP6 | |
| SCHEMBL14361241 | 0.88 | BRD3 (0.47) | BRD3ROCK2PARP1NAMPTGAA | |
| SCHEMBL5460537 | 0.87 | CDC42 (0.49) | ROCK2PARP1NAMPTCDC42GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | MAVS, SARS1, ZC3HAV1 | BRD3 529/4885ROCK2 2205/4885PARP1 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.